RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…
Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Albuminuria in healthy young adults 👉🏽https://t.co/p3M3zuDcCk ⚡️First-line Anti-HTN Medications 👉🏽https://t.co/5hQvC9D74T
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @Vilavaite: "The risk of nephrogenic systemic fibrosis from group II gadolinium-based contrast agent administration in stage 4 or 5 chro…
RT @DornbosIII_MD: Risk of 0% is pretty low ... contrast for everyone! https://t.co/IGMzu0qn9x
RT @nicopajes: ⚠️ Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @nicopajes: ⚠️ Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadoliniu…
RT @UMichRadiology: Congratulations former @UMichRadiology #RadRes, now #RadFellow @UCSFimaging Sean Woolen, MD for article: Risk of Nephr…
⚠️ Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis 🧐 https://t.co/agLzl1THCn https://t.co/qGDnlWEmIy
From @JAMA_current: Risk of nephrogenic systemic sclerosis in advanced #CKD after gadolinium for #MRI nears 0%. Makes you rethink withholding contrast MRIs for this purpose... https://t.co/xXyA9hba4F
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
In this systematic review/meta-analysis of 16 studies and 4931 patients, the pooled incidence of nephrogenic systemic fibrosis from group II gadolinium-based contrast agent in patients with stage 4 or 5 CKD was 0%; the upper bound of the 95% CI was 0.07% h
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
"The risk of nephrogenic systemic fibrosis from group II gadolinium-based contrast agent administration in stage 4 or 5 chronic kidney disease is <0.07% Potential diagnostic harms of withholding group II Gd-based contrast agents may outweigh the risk o
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Really a fantastic job by the whole team! Congratulations! @PrasadShankarMD @JAMAInternalMed
RT @UMichRadiology: Congratulations former @UMichRadiology #RadRes, now #RadFellow @UCSFimaging Sean Woolen, MD for article: Risk of Nephr…
Congratulations former @UMichRadiology #RadRes, now #RadFellow @UCSFimaging Sean Woolen, MD for article: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent See h
RT @mxhawkes: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Ba…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @DornbosIII_MD: Risk of 0% is pretty low ... contrast for everyone! https://t.co/IGMzu0qn9x
If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the patient’s kidneys are more important than their brain, this is welcome news!
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Title: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. (2019-12-10) Link: https://t.co/MnrhZEe7G4
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @jonherochung: Routine screening for renal failure when using a group II gadolinium agent is technically optional according to the ACR b…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @jonherochung: Routine screening for renal failure when using a group II gadolinium agent is technically optional according to the ACR b…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Wow! Anyone need a second round of contrast?! @VUMC_Neurosurg @VUMCradiology https://t.co/QONjtWnRe8
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @StephenTMagill: That is probably a risk worth taking, to characterize your brain tumor. https://t.co/cMMyir3JgO
Exceedingly low risk (<0.07%) of nephrogenic systemic fibrosis following administration of Group II Gadolinium contrast agents in patients with eGFR<30. #MRI #neuroradiology
Risk of 0% is pretty low ... contrast for everyone!
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
That is probably a risk worth taking, to characterize your brain tumor.
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
A very useful meta-analysis indeed. Need to find out what group of agent we use in our institute.
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https://t.co/1FKMNuYNCj
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis | Chronic Kidney Disease | JAMA Internal Medicine | JAMA Network https://
RT @graffeo: AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏 https://t.co/X4W3aelMXE
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
AN👏MRI👏WITHOUT👏CONTRAST👏IS👏LIKE👏A👏 NEUROSURGERY👏 CONSULT👏 WITHOUT👏 IMAGING👏
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
@tanimal07 JC?
Must read for all acute care physicians. @ACEPNow @EmergencyDocs @aceprogramsny @OhioACEP @californiaacep @CriticalCareNew @RadiologyACR @EMJNephrology @CDCemergency 4931 patients with CKD 4-5 received contrast CT study with ZERO nephrotoxicity https://t
RT @MRIvikas: Hugely important work from @PrasadShankarMD and @MattDavenportMD from @UMichRadiology, showing no NSF in nearly 5K patients w…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @JAMAInternalMed: Systematic review & meta-analysis by @umichradiology on the risk of NSF in patients w stage 4 or 5 chronic kidney dise…
RT @JAMAInternalMed: Systematic review & meta-analysis by @umichradiology on the risk of NSF in patients w stage 4 or 5 chronic kidney dise…